TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A randomized trial in 96 adults aged 18 to 45 with obesity and early-onset type 2 diabetes found that 54% of those assigned to a 24-week intensive diet-and-exercise program met the study’s remission definition, compared with about 4% receiving usual care. The result is promising but applies to a small, specific group and does not mean diabetes was permanently cured.
A 24-week randomized clinical trial found that 27 of 50 younger adults with obesity and early-onset type 2 diabetes—54% of the intensive-program group—met the study’s definition of remission, compared with 2 of 46 participants receiving usual care. The results, reported at the European Association for the Study of Diabetes annual meeting and published in The Lancet Regional Health Americas, concern a medically supervised program combining a low-calorie diet and exercise; remission does not mean the condition was permanently cured.
The trial enrolled 96 adults aged 18 to 45 who had early-onset type 2 diabetes and obesity and were not using insulin. Participants were randomly assigned either to continue standard care or to follow the intensive lifestyle program. The research took place at three centers in England and Canada, with 50 people assigned to the program and 46 to usual care. The study was open-label, meaning participants and researchers knew the assignment, while assessment of the main outcome was blinded.
For the first 12 weeks, the intervention prescribed 800 to 900 calories a day and supervised aerobic and resistance exercise twice weekly, plus one independent exercise session. Participants then moved to a diet intended to maintain weight loss and continued exercising independently through week 24. At the program’s start, glucose-lowering medication—and, under specified conditions, blood-pressure medication—was stopped with medical supervision. This was a trial protocol, not an instruction for people to change medication on their own.
Remission was defined as HbA1c below 6.5% (48 mmol/mol) with no glucose-lowering medication for at least 12 weeks. HbA1c reflects average blood glucose over roughly three months. Researchers included all randomized participants in their analysis and counted missing remission results as failures to achieve remission. 86 of 96 participants completed final assessments. The supplied report says the intervention group was statistically more likely to reach remission, but the 54% and approximately 4% figures are the direct group results.
A Potential Option for Younger Adults
Type 2 diabetes diagnosed at a younger age can mean more years living with the condition and its associated health risks. The researchers say early-onset diabetes is often linked with faster deterioration in blood-sugar control and earlier complications than diabetes diagnosed later in life. Against that backdrop, a result in which more than half of the intervention group met remission criteria suggests that an intensive lifestyle approach merits further study for younger adults with obesity and diabetes.
The comparison also matters because remission was uncommon in the usual-care group in this trial: 2 of 46 participants, or about 4%, met the same definition at 24 weeks. However, the findings do not show that every patient can safely follow this plan, that the effect will last, or that it prevents long-term complications. The calorie restriction was substantial and paired with structured oversight, so the result should not be treated as evidence for attempting the regimen without clinical support.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
How the Trial Measured Remission
Researchers led by Professor Kaberi Dasgupta of McGill University and Professor Thomas Yates of the University of Leicester tested whether adding structured exercise to a low-calorie diet could improve on approaches that use dietary weight loss alone. They enrolled participants between September 2021 and June 2025 at research centers affiliated with the University of Leicester, McGill University and the University of Alberta.
The program was staged rather than a six-month period of identical food replacement. For the first two weeks, participants received specially formulated meal replacements. From weeks three through 12, they retained the calorie target but could include one conventional meal each day, with specified protein, fruit and non-starchy vegetable targets. During weeks 13 through 24, the focus shifted to maintaining weight loss. The primary result is therefore about the full supervised 24-week package, not diet or exercise considered separately.
Remission in this study meant blood sugar below the diagnostic threshold while off glucose-lowering medication for a defined period. It is a clinical status measured at a point in time, not proof that diabetes has disappeared permanently. The trial’s 24-week outcome cannot establish how many participants will remain in remission over the longer term.
“The findings suggest that a low-calorie diet paired with regular exercise could significantly change the course of early-onset type 2 diabetes.”
— The study’s authors, as summarized in the supplied report
Long-Term Results Remain Unknown
The trial reports remission at 24 weeks; the supplied material does not establish whether participants maintained remission after that point. Longer follow-up is needed to understand how durable the result is and whether participants later resumed medication. It is also unclear from the provided report how the groups compared on longer-term complications or other clinical outcomes.
The study was relatively small, involving 96 participants at three centers, and its findings apply most directly to adults aged 18 to 45 with obesity and early-onset type 2 diabetes who were not using insulin. The supplied material does not give full details of adverse events, individual variation in weight loss, or how the program would perform in broader patient populations. The reported comparison is encouraging, but it is not a guarantee of an individual outcome.
Follow-Up Will Test Durability
The key next step is to learn whether remission persists beyond the study’s 24-week assessment, particularly as participants move from intensive weight loss to longer-term maintenance. Further reporting or follow-up from the researchers could clarify continued medication use, weight changes, safety findings and outcomes after the structured program ends. The supplied source does not specify a date for those results.
For now, the finding should be read as evidence from a controlled trial of a specific, supervised program—not as a general treatment recommendation. People with type 2 diabetes should discuss diet, exercise and medication decisions with a qualified health professional, especially because medication changes in this study took place under medical supervision.
Key Questions
What does the 54% figure mean?
27 of 50 participants assigned to the intensive program met the study’s remission criteria at 24 weeks. It does not mean that 54% of all people with type 2 diabetes can expect the same result.
How did the study define remission?
Participants needed an HbA1c below 6.5% and to have taken no glucose-lowering medication for at least 12 weeks. The definition does not establish a permanent cure.
What did the intensive program involve?
It combined a diet providing 800 to 900 calories daily during the initial 12 weeks with supervised aerobic and resistance exercise twice a week and one independent session. The second half focused on maintaining weight loss while participants continued exercising.
Can participants stop diabetes medication based on this result?
No. Medication changes in the trial were made under medical supervision. The study does not support stopping or changing medication without advice from a qualified health professional.
Does the trial show that remission lasts?
No. The reported outcome was measured at 24 weeks. The supplied material does not establish how many participants stayed in remission over a longer period.
Source: sciencedaily.com
